ArticleApplied microbiology and biotechnology2026
Photodynamic inactivation of Mycobacterium tuberculosis by broad-spectrum visible light.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multispectral Antimicrobial Blue Light (aBL) Systems for Continuous Decontamination of Food-Contact Surfaces and Environmental Matrices.Foods (Basel, Switzerland) · 2026Article
- Improving the Microbiological Safety of Raw Meat Through Visible Blue-Violet Light Irradiation.Foods (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis, a major infectious disease causing substantial global morbidity and mortality. The growing incidence of antibiotic-resistant strains highlights the urgency of identifying alternative strategies capable of targeting persistent and resistant forms of Mtb. This study evaluates the effectiveness of photodynamic inactivation (PDI) using visible light within the 400-420 nm range against a clinical Mtb isolate. The isolate was subjected to controlled LED exposure under biosafety level-3 conditions, with viability assessed via colony-forming unit counts. Results showed a significant reduction in Mtb viability, with > 99% (over 2-log) reduction observed after exposure to the tested visible light spectrum. These results provide a strong rationale for the clinical translation of visible light-based disinfection strategies, by indicating that visible light photoinactivation provides a practical, non-chemical alternative to conventional disinfectants and UV-based methods, reducing concerns about toxicity and operational limitations. This approach holds particular promise for healthcare environments, where it could contribute to reducing the environmental persistence of Mtb and, consequently, the risk of transmission. These results underscore the need for further investigation into light-based technologies as complementary tools to existing infection control measures, particularly in high-risk or inadequately sanitized settings. KEY POINTS: • Visible light (Soret Band 400-420 nm) significantly reduces Mycobacterium tuberculosis (Mtb) viability • No photosensitizers are used in the photodynamic inactivation (PDI) process • LED-based visible light may help limit Mtb spread in clinical environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.